1 – 94 of 94
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
(
- Contribution to journal › Article
-
Mark
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer's disease
2024) In bioRxiv : the preprint server for biology(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
2024) In JAMA(
- Contribution to journal › Article
-
Mark
Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders : An International, Multicenter Study
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer's disease
(
- Contribution to journal › Article
- 2023
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
(
- Contribution to journal › Article
-
Mark
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients
(
- Contribution to journal › Article
-
Mark
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
(
- Contribution to journal › Article
-
Mark
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
- 2022
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Age-related tau-PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A biomarker profile of elevated CSF p-tau with normal tau PET is associated with increased tau accumulation rates on PET in early Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Earlier Alzheimer's disease onset is associated with a shift of tau pathology towards brain hubs which facilitates tau spreading
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Hippocampal subregional thinning related to tau pathology in early stages of Alzheimer’s disease
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading
(
- Contribution to journal › Article
-
Mark
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline
(
- Contribution to journal › Article
-
Mark
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
(
- Contribution to journal › Article
-
Mark
Tau PET Imaging in Neurodegenerative Disorders
2022) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 63. p.20-26(
- Contribution to journal › Article
- 2021
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Sex differences in off-target binding using tau positron emission tomography
(
- Contribution to journal › Article
-
Mark
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
(
- Contribution to journal › Article
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article
- 2020
-
Mark
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
-
Mark
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Assessment of Demographic, Genetic, and Imaging Variables Associated with Brain Resilience and Cognitive Resilience to Pathological Tau in Patients with Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
(
- Contribution to journal › Letter
-
Mark
Plasma P-tau181 in Alzheimer’s disease : relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
(
- Contribution to journal › Article
-
Mark
Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET
(
- Contribution to journal › Article
-
Mark
No symphony without bassoon and piccolo : Changes in synaptic active zone proteins in Huntington's disease
(
- Contribution to journal › Article
-
Mark
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The implications of different approaches to define AT(N) in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
(
- Contribution to journal › Article
-
Mark
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
(
- Contribution to journal › Article
-
Mark
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease
(
- Contribution to journal › Article
- 2019
-
Mark
Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake
(
- Contribution to journal › Article
-
Mark
Correlation of in Vivo [18F]Flortaucipir with Postmortem Alzheimer Disease Tau Pathology
(
- Contribution to journal › Article
-
Mark
18
F-Flortaucipir in TDP-43 associated frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
A Deep Learning Approach to MR-less Spatial Normalization for Tau PET Images
2019) 22nd International Conference on Medical Image Computing and Computer-Assisted Intervention, MICCAI 2019 In Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) 11765 LNCS. p.355-363(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity
(
- Contribution to journal › Article
- 2018
-
Mark
Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people
(
- Contribution to journal › Article
-
Mark
Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders
(
- Contribution to journal › Article
-
Mark
18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies
(
- Contribution to journal › Article
-
Mark
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease : a cohort study
(
- Contribution to journal › Article
-
Mark
Comparing 18 F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
(
- Contribution to journal › Article
- 2017
-
Mark
Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau pathology distribution in Alzheimer's disease corresponds differentially to cognition-relevant functional brain networks
(
- Contribution to journal › Article
-
Mark
In vivo retention of (18)F-AV-1451 in corticobasal syndrome
(
- Contribution to journal › Article
-
Mark
Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology
(
- Contribution to journal › Article
- 2016
-
Mark
18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
(
- Contribution to journal › Article
-
Mark
Posterior accumulation of tau and concordant hypometabolism in an early-onset Alzheimer's disease patient with presenilin-1 mutation
(
- Contribution to journal › Article
-
Mark
18F-AV1451 pet detects tau pathology in mapt mutation carriers and correlates strongly with immunohistochemistry of tau aggregates
2016) Alzheimer’s Association International Conference 2016 In Alzheimer's and Dementia 12(7 Suppl). p.723-724(
- Contribution to journal › Published meeting abstract
- 2015
-
Mark
The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
(
- Contribution to journal › Article
- 2013
-
Mark
NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington's Disease
(
- Contribution to journal › Article
- 2009
-
Mark
Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment
(
- Contribution to journal › Article
-
Mark
Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion.
(
- Contribution to journal › Article
- 2008
-
Mark
Increased metabolism in the R6/2 mouse model of Huntington's disease.
(
- Contribution to journal › Article
- 2007
-
Mark
Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line - Studies in vitro and after intracerebral grafting in vivo
(
- Contribution to journal › Article
-
Mark
Communication breakdown - synaptic dysfunction in Huntington's disease.
2007)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease.
(
- Contribution to journal › Article
- 2006
-
Mark
Cholinergic neuronal defect without cell loss in Huntington's disease.
(
- Contribution to journal › Article
- 2005
-
Mark
Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
(
- Contribution to journal › Article
-
Mark
Orexin loss in Huntington's disease.
(
- Contribution to journal › Article
-
Mark
Synaptic dysfunction in Huntington's disease: a new perspective
(
- Contribution to journal › Scientific review
- 2003
-
Mark
Fria radikaler och sjuka proteiner - bovarna bakom Parkinsons sjukdom?[Free radicals and ailing proteins - the culprits behind Parkinson’s disease?]
(
- Contribution to journal › Article